Collusion as an Informed Principal Problem

2005 ◽  
Author(s):  
Lucia Quesada
Keyword(s):  
Principal Problem ◽  
Informed Principal

scholarly journals Informed-principal problem with moral hazard, risk neutrality, and no limited liability

2015 ◽  
Vol 159 ◽  
pp. 280-289 ◽  
Author(s):  
Christoph Wagner ◽  
Tymofiy Mylovanov ◽  
Thomas Tröger
Keyword(s):  
Moral Hazard ◽  
Limited Liability ◽  
Principal Problem ◽  
Informed Principal ◽  
Hazard Risk

scholarly journals Selling with evidence

2019 ◽  
Vol 14 (2) ◽  
pp. 345-371
Author(s):  
Frédéric Koessler ◽  
Vasiliki Skreta
Keyword(s):  
Asymmetric Information ◽  
Product Quality ◽  
Optimal Allocation ◽  
Pareto Optimal ◽  
Principal Problem ◽  
Equilibrium Allocation ◽  
Interdependent Values ◽  
Ex Ante ◽  
Private Value ◽  
Posted Price

We study the informed‐principal problem in a bilateral asymmetric information trading setting with interdependent values and quasi‐linear utilities. The informed seller proposes a mechanism and voluntarily certifies information about the good's characteristics. When the set of certifiable statements is sufficiently rich, we show that there is an ex ante profit‐maximizing selling procedure that is an equilibrium of the mechanism proposal game. In contrast to posted price settings, the allocation obtained when product characteristics are commonly known (the unravelling outcome) may not be an equilibrium allocation, even when all buyer types agree on the ranking of product quality. Our analysis relies on the concept of strong Pareto optimal allocation, which was originally introduced by Maskin and Tirole (1990) in private value environments.

scholarly journals THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

2013 ◽  
Vol 5 (1) ◽  
pp. e2013050 ◽  
Author(s):  
Elihu Estey
Keyword(s):  
Life Expectancy ◽  
Supportive Care ◽  
Low Dose ◽  
Best Supportive Care ◽  
Therapeutic Options ◽  
Intensive Chemotherapy ◽  
Principal Problem

Although “less intense” therapies are finding more use in AML, the principal problem in AML remains lack of efficacy rather than toxicity. Hence less intense therapies are of little use if they are not more effective as well as less toxic than standard therapies.. Assignment of patients to less intense therapies should be based on other factors in addition to age. Azacitidine and decitabine, the most commonly used less intense therapies in AML very probably produce better OS than best “supportive care” or “low-dose” ara-C. However improvement is relatively small when compared to expected life expectancy in the absence of disease. Accordingly, while azacitidine or decitabine should be considered the standards against which newer therapies are compared, continued investigation of potentially more effective therapies needs to continue. Better means for evaluating the large number of these therapies (and their combinations) are also needed.   

scholarly journals Informed-principal problems in environments with generalized private values

10.3982/te787 ◽  
2012 ◽  
Vol 7 (3) ◽  
pp. 465-488 ◽  
Author(s):  
Tymofiy Mylovanov ◽  
Thomas Tröger
Keyword(s):  
Informed Principal ◽  
Private Values
Sign in / Sign up

Export Citation Format

Share Document